Premium
Neuropeptide Y in human hand veins: Pharmacologic characterization and interaction with cyclic guanosine monophosphate‐dependent venodilators in vivo
Author(s) -
Peduzzi Paolo,
Simper David,
Linder Lilly,
Strobel Werner M.,
Haefeli Walter E.
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90024-1
Subject(s) - neuropeptide y receptor , endocrinology , medicine , neuropeptide , in vivo , ed50 , phenylephrine , vasoconstriction , bradykinin , somatostatin , chemistry , biology , receptor , microbiology and biotechnology , blood pressure
The dorsal hand vein compliance technique was used to study direct vascular effects of human neuropeptide Y in vivo. Human neuropeptide Y is an endogenous vasoconstrictor peptide that is costored with norepinephrine in sympathetic nerve endings and coreleased with the catecholamine under various physiologic and pathologic conditions. Compared with the α 1 ‐adrenergic agonist phenylephrine (geometric mean dose‐rate that produces the half‐maximal response [ED 50 ]: 1.05 nmol/min; maximum venoconstriction [E max ] ±SEM, expressed as a percentage of baseline compliance: 91% ± 3%), human neuropeptide Y was nine times more potent (geometric mean ED 50 : 0.122 nmol/min; p < 0.001) but markedly less efficacious (E max : 58% ± 4%; n = 12; p < 0.001). Venoconstrictor effects of human neuropeptide Y lasted several hours and were unchanged by simultaneous administration of α‐adrenergic antagonists but were readily reversed by nitroglycerin or bradykinin. The high responsiveness of subcutaneous veins to human neuropeptide Y indicates that human neuropeptide Y may regulate venous compliance and filling of the venous subcutaneous capacitance bed in vivo. Clinical Pharmacology & Therapeutics (1995) 58 , 675–683; doi: